UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 211

Sortiert nach

Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy

Scientific reports, 2018-05, Vol.8 (1), p.7675-11, Article 7675

2018

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis

Scientific reports, 2021-04, Vol.11 (1), p.9132-9132, Article 9132

2021

Link zum Volltext

Verfügbarkeit prüfen

SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis

Scientific reports, 2022-05, Vol.12 (1), p.8579-8579, Article 8579

2022

Link zum Volltext

Verfügbarkeit prüfen

Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways

Frontiers in immunology, 2022-05, Vol.13, p.884399-884399

2022

Link zum Volltext

Verfügbarkeit prüfen

Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage

Cancer cell, 2005-07, Vol.8 (1), p.49-59

2005

Link zum Volltext

Verfügbarkeit prüfen

Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma

ACS medicinal chemistry letters, 2018-02, Vol.9 (2), p.98-102

2018

Link zum Volltext

Verfügbarkeit prüfen

A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer

OncoTargets and therapy, 2021, Vol.14, p.4561-4574

2021

Link zum Volltext

Verfügbarkeit prüfen

Mechanistically Probing Lipid-siRNA Nanoparticle-associated Toxicities Identifies Jak Inhibitors Effective in Mitigating Multifaceted Toxic Responses

Molecular therapy, 2011-03, Vol.19 (3), p.567-575

2011

Link zum Volltext

Verfügbarkeit prüfen

Ubiquitin-conjugating enzyme UbcH10 promotes gastric cancer growth and is a potential biomarker for gastric cancer

Oncology reports, 2016-08, Vol.36 (2), p.779-786

2016

Link zum Volltext

Verfügbarkeit prüfen

Nucleocytoplasmic Shuttling of Oncoprotein Hdm2 Is Required for Hdm2-Mediated Degradation of p53

Proceedings of the National Academy of Sciences - PNAS, 1999-03, Vol.96 (6), p.3077-3080

1999

Link zum Volltext

Verfügbarkeit prüfen

The Mitotic Checkpoint in Cancer Therapy

Cell cycle (Georgetown, Tex.), 2005-11, Vol.4 (11), p.1495-1499

Tao, Weikang

2005

Link zum Volltext

Verfügbarkeit prüfen

Discovery of EBI-907: A highly potent and orally active B-Raf V600E inhibitor for the treatment of melanoma and associated cancers

Bioorganic & medicinal chemistry letters, 2016-02, Vol.26 (3), p.819-823

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of SHR9352: A Highly Potent G Protein-Biased μ‑Opioid Receptor Agonist

ACS omega, 2017-12, Vol.2 (12), p.9261-9267

2017

Link zum Volltext

Verfügbarkeit prüfen

An Inhibitor of the Kinesin Spindle Protein Activates the Intrinsic Apoptotic Pathway Independently of p53 and De Novo Protein Synthesis

Molecular and Cellular Biology, 2007-01, Vol.27 (2), p.689-698

2007

Link zum Volltext

Verfügbarkeit prüfen

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

European journal of pharmaceutical sciences, 2017-12, Vol.110, p.51-61

2017

Link zum Volltext

Verfügbarkeit prüfen

Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic

Pharmacology & therapeutics (Oxford), 2019-11, Vol.203, p.107393-107393, Article 107393

2019

Link zum Volltext

Verfügbarkeit prüfen

Pyridyl aminothiazoles as potent Chk1 inhibitors: Optimization of cellular activity

Bioorganic & medicinal chemistry letters, 2012-04, Vol.22 (7), p.2613-2619

2012

Link zum Volltext

Verfügbarkeit prüfen

Kinesin spindle protein (KSP) inhibitors. Part V: Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein

Bioorganic & medicinal chemistry letters, 2007-05, Vol.17 (10), p.2697-2702

2007

Link zum Volltext

Verfügbarkeit prüfen

Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP

Bioorganic & medicinal chemistry letters, 2006-04, Vol.16 (7), p.1775-1779

2006

Link zum Volltext

Verfügbarkeit prüfen

Kinesin spindle protein (KSP) inhibitors. Part 4: Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP

Bioorganic & medicinal chemistry letters, 2006-06, Vol.16 (12), p.3175-3179

2006

Link zum Volltext

Verfügbarkeit prüfen

Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP

Bioorganic & medicinal chemistry letters, 2007-10, Vol.17 (20), p.5677-5682

2007

Link zum Volltext

Verfügbarkeit prüfen

3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6

Bioorganic & medicinal chemistry letters, 2006-12, Vol.16 (23), p.6049-6053

2006

Link zum Volltext

Verfügbarkeit prüfen

Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors

Bioorganic & medicinal chemistry letters, 2007-11, Vol.17 (21), p.5989-5994

2007

Link zum Volltext

Verfügbarkeit prüfen

Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors

Bioorganic & medicinal chemistry letters, 2006-11, Vol.16 (22), p.5907-5912

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 211

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(202)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(160)
Life Sciences & Biomedicine
(87)
Technology
(57)
Physical Sciences
(55)
Chemistry
(41)
Engineering
(38)
Animals
(35)
Humans
(34)
Pharmacology & Pharmacy
(29)
Chemistry, Medicinal
(24)
Science & Technology - Other Topics
(22)
Engineering, Chemical
(21)
Mice
(21)
Materials Science
(19)
Chemistry, Physical
(17)
Physics
(17)
Cell Line, Tumor
(16)
Oncology
(16)
Proteins
(16)
Cancer
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy

Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis

SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis

Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways

Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage

Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma

A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer

Mechanistically Probing Lipid-siRNA Nanoparticle-associated Toxicities Identifies Jak Inhibitors Effective in Mitigating Multifaceted Toxic Responses

Ubiquitin-conjugating enzyme UbcH10 promotes gastric cancer growth and is a potential biomarker for gastric cancer

Nucleocytoplasmic Shuttling of Oncoprotein Hdm2 Is Required for Hdm2-Mediated Degradation of p53

Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer

The Mitotic Checkpoint in Cancer Therapy

Discovery of EBI-907: A highly potent and orally active B-Raf V600E inhibitor for the treatment of melanoma and associated cancers

Discovery of SHR9352: A Highly Potent G Protein-Biased μ‑Opioid Receptor Agonist

An Inhibitor of the Kinesin Spindle Protein Activates the Intrinsic Apoptotic Pathway Independently of p53 and De Novo Protein Synthesis

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic

Pyridyl aminothiazoles as potent Chk1 inhibitors: Optimization of cellular activity

Kinesin spindle protein (KSP) inhibitors. Part V: Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein

Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP

Kinesin spindle protein (KSP) inhibitors. Part 4: Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP

Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP

3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6

Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors

Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors

Suchergebnisse filtern